The Next Generation Vaccine Card: Innovative Technology to Improve Vaccine Equity in Rural and Urban Settings in East Africa
Launched by UNIVERSITY OF MICHIGAN · Jun 17, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new digital vaccine card and a mobile app designed to help improve access to vaccines in both rural and urban areas of East Africa, specifically in Uganda and Kenya. The goal is to see how well this new technology works, how much it costs, and whether it helps make the vaccination process fairer for everyone. The research team will also look at how accurate the information in this digital system is and how it can benefit different communities.
To be eligible for this trial, participants need to be between 1 day and 24 months old. Unfortunately, if a participant's location is not part of the study, they will not be able to take part. Those who join can expect to help test this innovative technology, which could potentially make it easier for families to keep track of vaccinations for their young children. This study is currently recruiting participants, and it aims to gather valuable insights that could improve vaccine distribution in these regions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1 day to 24 months old
- Exclusion Criteria:
- • Sites not included in the study
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nairobi, , Kenya
Kasese, , Uganda
Patients applied
Trial Officials
Emily Treleaven, PhD, MPH
Principal Investigator
University of Michigan
Gershim Asiki, MBChB, MSc, PhD
Principal Investigator
African Population and Health Research Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported